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Since November 2015, Puerto Rico has reported active 
mosquito-borne transmission of Zika virus (1). Because of 
the potential for Zika virus to be transmitted through trans-
fusion of blood components, and because a high percentage 
of persons infected with Zika virus are asymptomatic (2), the 
Food and Drug Administration (FDA) recommended that 
blood collections cease in areas of the United States affected 
by active vector-borne transmission of Zika virus until labo-
ratory screening of blood donations or pathogen reduction 
technology (PRT)* for treatment of blood components can 
be implemented (3). To inform efforts to maintain the safety 
and availability of the blood supply in Puerto Rico, CDC, in 
collaboration with the Puerto Rico Department of Health, 
conducted a rapid assessment of blood collection and use on 
the island. A total of 139,369 allogeneic red blood cell (RBC) 
units,† 45,243 platelet units, and 56,466 plasma units were col-
lected in or imported to Puerto Rico during 2015, and 135,966 
allogeneic RBC units, 13,526 therapeutic platelet units,§ and 
25,775 plasma units were transfused. Because of the potential 
for local Zika virus transmission in areas with a competent 
mosquito vector (4), other areas of the United States should 
develop plans to ensure local blood safety and adequacy. Blood 
collection organizations and public health agencies should col-
laborate to maintain the safety and availability of local blood 
supplies in accordance with FDA guidance.
Before this survey, no estimates of blood collection and use 
in Puerto Rico were available. The survey, conducted during 
February 10–24, 2016, included all blood collection centers 
performing local collections and importing blood components 
from the mainland United States for routine clinical use, 
as well as hospitals performing transfusions in Puerto Rico 
during 2015. The survey was based on a modified version of 
the 2015 National Blood Collection and Utilization Survey 
administered by CDC on behalf of the U.S. Department of 
Health and Human Services (5), in which U.S. territories 
have previously not been included. The survey included 
questions about donor blood collection methods and product 
types, importation of blood products for routine use, blood 
use, and extent of PRT implementation for platelets and 
plasma. Questionnaires were electronically distributed to the 
laboratory manager or medical director of each facility and 
were self-administered. Total collections and transfusions of 
whole blood, whole blood derived (WBD) RBC, platelet, 
plasma, and cryoprecipitate units (including total numbers 
of blood components imported from the continental United 
States), as well as RBC, platelet, and plasma units collected via 
apheresis¶ methods were tabulated. Estimates of transfusion 
were weighted for nonresponse using inpatient surgical volume 
(the average number of surgical procedures performed annually 
at a hospital) as a proxy for the amount of blood used annually, 
and 95% confidence intervals were estimated.
All 12 (100%) blood collection centers and 51 (91.1%) of 
56 hospitals performing transfusions responded to the sur-
vey. During 2015, a total of 82,381 whole blood units were 
reported to have been collected in Puerto Rico. These whole 
blood units yielded WBD components, including 80,431 
allogeneic RBC units, 32,753 individual platelet units, 47,055 
plasma units, and 4,615 cryoprecipitate units. RBCs, platelets, 
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* Chemical and/or ultraviolet light treatment to achieve reduction of risk for 
transfusion-transmitted infection. PRT is currently approved by the Food and 
Drug Administration (FDA) only for plasma and platelets derived from apheresis 
methods. It is not FDA-approved for red blood cells.
† Allogeneic blood components are collected from donors for transfusion into 
another person.
§ A unit of platelets prepared for transfusion from pooled individual whole blood 
derived platelet units.
¶ A medical technology that involves the withdrawal of blood from a donor, 
removal of one or more blood components (e.g., plasma or platelets), and 
transfusion of the remaining blood back into the donor.
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and plasma collections using apheresis methods were reported 
in much fewer numbers than those derived from whole blood 
(Table 1). PRT was used only to treat apheresis platelets, and 
constituted 1,403 (25.6%) of the 5,467 apheresis platelet 
collections. An additional 52,411 RBC units, 7,023 apheresis 
platelet units, 7,906 plasma units, and 2,651 cryoprecipitate 
units were imported from the continental United States for 
routine use in 2015. A total of 135,966 allogeneic RBC units, 
13,526 therapeutic platelet units, and 25,775 plasma units were 
transfused in 2015 (Table 2). Only 511 (36.4%) of the 1,403 
PRT-treated platelet units were transfused by hospitals in 2015.
Discussion
No blood transfusion-transmitted cases of Zika virus 
infection have been confirmed in Puerto Rico or the U.S. 
mainland (4); however, Zika virus nucleic acid was detected 
retrospectively in 2.8% of asymptomatic blood donors during 
a 2013–2014 Zika virus disease outbreak in French Polynesia 
(6), and transfusion-transmitted Zika virus infection has been 
reported in Brazil (7), where substantial Zika virus transmission 
is occurring. Because a large percentage of persons infected 
with Zika virus are asymptomatic (2), the risk for transfusion-
transmitted Zika virus infection in Puerto Rico and other areas 
of the United States and its territories is of concern.
In Puerto Rico, the majority of whole blood units and blood 
component units collected during 2015 were collected locally, 
placing a large proportion of the local blood supply at potential 
risk for transfusion-transmitted Zika virus infection. Whereas 
PRT is FDA-approved for plasma and apheresis platelets, and 
could be used to treat portions of the blood supply in accor-
dance with FDA guidance, a lower than expected proportion 
of the platelet supply was derived from apheresis methods in 
Puerto Rico compared with the continental United States, 
where in 2013, 95% of all platelets were collected via apheresis 
(5); this difference might have been related to cost of imple-
mentation of apheresis methods in Puerto Rico. In addition, 
PRT is not FDA-approved for whole blood or RBCs, the most 
commonly transfused WBD component. These factors resulted 
in a risk for critical blood shortages as local blood collections in 
Puerto Rico were recommended to cease on March 1, 2016, in 
accordance with FDA guidance, until a nucleic acid screening 
test could be implemented for blood collections under inves-
tigational protocols beginning on April 4, 2016 (8).
The results of this survey were used to guide a federally 
supported coordinated effort to address the blood supply and 
safety challenges in Puerto Rico, which included importation 
of all blood components from the continental United States at a 
volume sufficient to meet the demand projected from the 2015 
estimates, beginning on March 5, 2016 (9). Local collections 
resumed in Puerto Rico on April 2, 2016, after FDA approved 
blood donations in the United States to be screened for Zika 
infection using an investigational nucleic acid test developed 
by Roche Molecular Systems (Branchburg, New Jersey) (8). 
In addition, efforts to implement PRT for apheresis platelets 
and plasma collections in Puerto Rico are currently under 
way, and evaluation trials to determine safety and efficacy of 
investigational PRT for RBCs are in planning stages.
The findings in this report are subject to at least three limi-
tations. First, survey data were self-reported by facilities and 
could not be independently verified. Second, although the 
survey response rate was high, results were limited by missing 
responses to some questions, leading to uncertainty regarding 
the estimates. Finally, although English language assistance 
was available to respondents, each of whom was contacted 
directly by a Spanish-speaking team member to ensure receipt 
of the survey and inquire about the need for assistance, the 
survey instrument was written in English, which might have 
TABLE 1. Number of units of blood and blood components 
collected by all 12 of the country’s blood collection centers or 
imported from the continental United States for routine clinical 
use — Puerto Rico, 2015
Component type
No. of units 
collected
No. of units 
imported Total units
Whole blood collections 82,381 0 82,381
Red blood cells (RBCs)
Apheresis* RBCs 5,280 16,575 21,855
Allogeneic WBD RBCs 80,431 35,836 116,267
Autologous WBD RBCs 396 0 396
Directed WBD RBCs 851 0 851
Total RBC collections 86,958 52,411 139,369
Platelets
Apheresis platelets 5,467 7,023 12,490
Apheresis platelets prepared 
using pathogen reduction 
technology (PRT)†
1,403 0 1,403
Individual WBD platelets§ 32,753 0 32,753
Total platelet collections 38,220 7,023 45,243
Plasma
Apheresis plasma 1,505 2 1,507
WBD plasma 47,055 7,904 54,959
Total plasma collections 48,560 7,906 56,466
Plasma prepared using PRT 0 0 0
Other
Individual cryoprecipitate 4,615 2,651 7,266
Abbreviation: WBD = whole blood derived.
* A medical technology that involves the withdrawal of blood from a donor, 
removal of one or more blood components (e.g., plasma or platelets), and 
transfusion of the remaining blood back into the donor.
† Chemical and/or ultraviolet light treatment to achieve reduction of risk for 
transfusion-transmitted infection. PRT is currently approved by the Food and 
Drug Administration (FDA) only for plasma and platelets derived from apheresis 
methods. It is not FDA-approved for red blood cells.
§ WBD platelets were reported as individual units. These units are pooled to 
result in a standard adult dose. The average pool size for whole blood derived 
platelets was 5.8 individual doses.
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affected the interpretation of questions by staff members in 
blood collection centers and hospitals; the impact on the survey 
findings is not known.
The risk for transfusion-transmitted Zika virus infection 
presents a current challenge to the safety and availability of 
the blood supply in Puerto Rico and an emerging threat to 
other areas of the United States, where Zika virus might spread 
via mosquito-borne transmission, particularly given the risk 
for clinical complications associated with infection, includ-
ing Guillain-Barré syndrome and congenital abnormalities 
in infants born to women infected during pregnancy (10). 
Because of the high rate of asymptomatic infection (2), blood 
donor screening without a laboratory test is insufficient for 
identifying infected donors in areas with active transmission. 
Interventions to prevent transfusion-transmitted Zika virus 
infection in areas of the United States that do not have active 
mosquito-borne transmission include donation deferral for 
those who have had Zika virus infection (deferral for 4 weeks 
after symptom resolution) or symptoms suggestive of Zika 
virus infection during the past 4 weeks, those who have had 
sexual contact with a person with Zika virus infection or who 
has traveled to, or resided in, an area with active Zika virus 
transmission during the prior 3 months, and those who have 
traveled to areas with active transmission of Zika virus during 
the past 4 weeks (3). In areas with current mosquito-borne Zika 
virus transmission, importation of blood components from 
unaffected areas is recommended until nucleic acid testing is 
implemented or PRT, as applicable, is adopted.
Outsourcing of blood components from unaffected areas 
might not be feasible if there is widespread Zika virus transmis-
sion in heavily populated areas of the continental United States. 
Therefore, it is important to maintain local blood collections in 
the continental United States. The availability of safe blood is a 
critical need for health care, and collaboration between blood 
collection organizations and health departments is essential 
to comply with FDA guidance, including implementation 
of laboratory testing of blood donations or use of PRT with 
plasma units and apheresis platelets.
TABLE 2. Weighted estimates of the number of units of blood and 
blood components transfused and number of hospitals (N = 56) 
responding to the survey — Puerto Rico, 2015
Component type
No. of units 
transfused*
No. of 
hospitals 
responding (95% CI)
Whole blood units
Allogeneic† 0 27 —
Directed§ 0 28 —
Autologous¶ 22 28 (0–68)
Red blood cells
Allogeneic 135,966 47 (110,856–161,075)
Directed 2,338 32 (0–6,288)
Autologous 357 36 (29–684)
Platelets
Whole blood derived (WBD**) 22,054 31 (4,768–39,339)
Apheresis†† platelets 9,724 44 (5,590–13,857)
Apheresis platelets prepared 
using pathogen reduction 
technology (PRT)§§
511 44 (0–1,278)
Plasma
Total 25,775 46 (15,935–35,615)
Plasma prepared using PRT 0 23 —
Abbreviation: CI = confidence interval.
 * Weighted for nonresponse in a population of 56 hospitals.
 † Collected from donors for transfusion into another person.
 § Donations intended for a specific recipient.
 ¶ Donations by individuals for their own use, often for an elective procedure 
or planned transfusion.
 ** WBD platelets were reported as individual units. These units are pooled to 
result in a standard adult dose. The average pool size for whole blood derived 
platelets was 5.8 individual doses.
 †† A medical technology that involves the withdrawal of blood from a donor, 
removal of one or more blood components (e.g., plasma or platelets), and 
transfusion of the remaining blood back into the donor.
 §§ Chemical and/or ultraviolet light treatment to achieve reduction of risk for 
transfusion-transmitted infection. PRT is currently approved by the Food and 
Drug Administration (FDA) only for plasma and platelets derived from 
apheresis methods. It is not FDA-approved for red blood cells.
Summary
What is already known about this topic?
Because of the potential for transfusion-associated transmission 
of Zika virus, the Food and Drug Administration (FDA) has 
recommended deferral of blood donors in affected U.S. areas 
until blood donations can be screened by nucleic acid testing or 
blood products can be subjected to FDA-approved pathogen 
reduction technology (PRT). FDA has recommended that whole 
blood and blood components for transfusion be obtained from 
U.S. areas without active Zika virus transmission.
What is added by this report?
Puerto Rico is experiencing active Zika virus transmission and 
also performs local blood collections. Therefore, Puerto Rico is 
the first U.S. area to need to comply with FDA guidance. 
Historically, Puerto Rico has also imported blood from the U.S. 
mainland for routine purposes. Outsourcing of blood compo-
nents from unaffected areas might not be feasible if there is 
widespread Zika virus transmission in heavily populated areas 
of the continental United States. Therefore, local blood collec-
tions should be maintained through the use of nucleic acid 
screening or PRT.
What are the implications for public health practice?
Importation of blood products from nonaffected areas might 
serve a role in prevention of transfusion-transmitted Zika virus. 
An approved laboratory test for blood donor screening and 
implementation of PRT are critical for compliance with FDA 
guidance and to ensure a safe and sustainable blood supply. 
Blood collection organizations and public health organizations 
need to collaborate to prepare for blood safety and adequacy 
challenges that might arise if Zika virus transmission spreads in 
the United States.
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